Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/592
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Sodium Iodide I 131 (Capsule)
|
| dailymed-instance:dosage |
The suggested oral dosage ranges employed in the average patient (70 kg) for diagnostic procedures for thyroid function are as follows: Thyroid Uptake: 0.185 to 0.555 megabecquerels (5 to 15 microcuries) Scintiscanning:1.85 to 3.7 megabecquerels (50 to 100 microcuries) Localization of extra-thyroidal metastases: 37 megabecquerels (1000 microcuries). Waterproof gloves should be used during the entire handling and administration procedure. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.
|
| dailymed-instance:descripti... |
Sodium Iodide 131 (NaI) for diagnostic use is supplied for oral administration in opaque white gelatin capsules. The capsules are available in a strength of 3.7 megabecquerels (100 microcuries) iodine I-131 at the time of calibration. Sodium Iodide I 131 Capsules are prepared by absorbing a solution of carrier-free sodium iodide I-131 into inert fillers. The iodine I-131 utilized in the preparation of the capsules contains not less than 99% iodine I-131 at the time of calibration.
|
| dailymed-instance:clinicalP... |
Sodium Iodide is readily absorbed from the gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is concentrated and organified by the thyroid, and trapped but not organified by the stomach and salivary glands. It is also promptly excreted by the kidneys.<br/>Indications and Usage: Sodium Iodide I 131 is indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Diagnostic doses may also be employed in localizing metastases associated with thyroid malignancies.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
None.
|
| dailymed-instance:supply |
Catalog Number 300. Sodium Iodide I 131 Diagnostic Capsules are supplied in a strength of 3.7 megabecquerels (100 microcuries) at time of calibration. The capsules are packaged in plastic vials containing 5, 10, or 15 capsules per vial.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
General: The uptake of radioiodide will be affected by recent intake of stable iodine in any form, or by the use of thyroid, anti-thyroid and certain other drugs. Accordingly, the patient should be questioned carefully regarding previous medication and procedures involving radiographic contrast media. The expiration date is not later than two months from the date of manufacture. The calibration date and the expiration date are stated on the container label. As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility: No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.<br/>Pregnancy Category C: Animal reproduction studies have not been conducted with Sodium Iodide I 131 Diagnostic Capsules. It is also not known whether Sodium Iodide I 131 Diagnostic Capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Iodide I 131 Diagnostic Capsules should be given to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceutical drug products���especially those elective in nature���of women of childbearing capability should be performed during the first ten days following the onset of menses.<br/>Nursing Mothers: Radioiodine is excreted in human milk during lactation. Therefore, formula feedings should be substituted for breast feedings.<br/>Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
|
| dailymed-instance:genericMe... |
Sodium Iodide, I-131
|
| dailymed-instance:fullName |
Sodium Iodide I 131 (Capsule)
|
| dailymed-instance:adverseRe... |
Although rare, reactions associated with the administration of iodine containing radiopharmaceuticals for diagnostic use include, in decreasing order of frequency, nausea, vomiting, chest pain, tachycardia, itching skin, rash and hives.
|
| dailymed-instance:warning |
None.
|
| dailymed-instance:indicatio... |
Sodium Iodide I 131 is indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Diagnostic doses may also be employed in localizing metastases associated with thyroid malignancies.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Sodium Iodide I 131
|